15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering AnaptysBio Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $50.00 to $100.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $80.45 sits 42% above the current $56.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -62% this year and 92% next, consensus EPS building from about $0.48 next quarter toward $5.24 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to AnaptysBio Inc.
As of Sep, 10 of 11 firms rate ANAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ANAB EPS & revenue forecast
EPS · NEXT QUARTER
$0.48
Range $-0.07 – $1.29 · 5 analysts · -8% YoY
Next period, 5 analysts expect AnaptysBio Inc to earn $0.48 a share (range $-0.07 – $1.29), versus $0.52 a year earlier. Full-year consensus is $-0.23, growing to $5.24 the year after.
REVENUE · NEXT QUARTER
$26.3M
Range $0 – $51.4M · 5 analysts · -30% YoY
Revenue is expected to reach $26.3M (range $0 – $51.4M), -30.0% year-over-year. Full-year consensus is $105.7M, rising to $172.2M next year.
Top analysts covering AnaptysBio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANAB.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$140.00+147.5% to target
Overall win rate
53%
+ Follow
#2
David Nierengarten
Wedbush · Rank #66
Buy
$75.00+32.6% to target
Overall win rate
42%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #75
Buy
$70.00+23.7% to target
Overall win rate
51%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$93.00+64.4% to target
Overall win rate
33%
+ Follow
#5
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$95.00+67.9% to target
Overall win rate
34%
+ Follow
ANAB stock forecast FAQ
What is ANAB's average 12-month price target?+
The 11 analysts with a live target average $80.45 for AnaptysBio Inc over the next 12 months, ranging from a $100.00 high to a $50.00 low.
Is ANAB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ANAB?+
The Street-high target is $100.00 (Guggenheim), and the Street-low is $50.00 (Truist Securities). The average of all 11 active targets is $80.45.
How many Wall Street analysts cover ANAB?+
11 analysts have an active rating on AnaptysBio Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering ANAB?+
Among analysts who currently cover ANAB, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $140.00 target.
What is AnaptysBio Inc's projected EPS for next quarter?+
The consensus estimate is $0.48 per share (range $-0.07 – $1.29) across 5 analysts. Full-year EPS is projected at $-0.23, rising to $5.24 the following year.
How much revenue is AnaptysBio Inc expected to report next quarter?+
Consensus revenue is $26.3M (range $0 – $51.4M). Full-year revenue is projected at $105.7M, growing to $172.2M next year.
Have analysts been upgrading or downgrading ANAB lately?+
As of Sep, 10 of 11 firms rate ANAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
